aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.52727/2078-256X-2021-17-4-20-27ateroskleroz-540Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESАссоциация параметров липидного профиля, индекса атерогенности плазмы, антропометрических показателей с тяжестью течения covid-19 у женщин г. НовосибирскаAssociation of lipid profile parameters, atherogenic index of plasma, anthropometric parameters with the severity of the COVID-19 course in Novosibirsk womenhttps://orcid.org/0000-0003-3772-1058ЕвдокимоваН. Е.EvdokimovaN. E.

Евдокимова Наталья Евгеньевна, младший научный сотрудник лаборатории генетических и средовых детерминант жизненного цикла человека, аспирантка

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

Natalia E. Evdokimova, junior researcher, laboratory of genetic and environmental determinants of the human life cycle

630089, Novosibirsk, Boris Bogatkov str., 175/1

tusya_evdokimova@mail.ruhttps://orcid.org/0000-0001-5316-4664СтрюковаЕ. В.StriukovaE. V.

Стрюкова Евгения Витальевна, младший научный сотрудник лаборатории генетических и средовых детерминант жизненного цикла человека

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

Evgeniia V. Striukova, junior researcher, laboratory of genetic and environmental determinants of the human life cycle

630089, Novosibirsk, Boris Bogatkov str., 175/1

stryukova.j@mail.ruhttps://orcid.org/0000-0002-3650-621XМаслацовН. А.MaslatsovN. A.

Маслацов Николай Анатольевич, младший научный сотрудник лаборатории генетических и средовых детерминант жизненного цикла человека, аспирант

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

Nikolay A. Maslatsov, junior researcher, laboratory of genetic and environmental determinants of the human life cycle

630089, Novosibirsk, Boris Bogatkov str., 175/1

maslatsoff@mail.ruhttps://orcid.org/0000-0001-7875-1566ХудяковаА. Д.KhudyakovaA. D.

Худякова Алена Дмитриевна, канд. мед. наук, зав. лабораторией генетических и средовых детерминант жизненного цикла человека

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

Alyona D. Khudyakova, PhD, Head of laboratory of genetic and environmental determinants of the human life cycle

630089, Novosibirsk, Boris Bogatkov str., 175/1

alene.elene@gmail.comhttps://orcid.org/0000-0003-1973-2618ВолковаМ. В.VolkovaM. V.

Волкова Марина Васильевна, младший научный сотрудник лаборатории генетических и средовых детерминант жизненного цикла человека, ординатор

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

Marina V. Volkova, junior researcher, laboratory of genetic and environmental determinants of the human life cycle

630089, Novosibirsk, Boris Bogatkov str., 175/1

https://orcid.org/0000-0003-1348-0253ЛогвиненкоИ. И.LogvinenkoI. I.

Логвиненко Ирина Ивановна, главный научный сотрудник лаборатории профилактической медицины, д-р мед. наук, проф., зам. руководителя по лечебной работе

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

Irina I. Logvinenko, doctor of medical sciences, professor, chief researcher, laboratory of preventive medicine

630089, Novosibirsk, Boris Bogatkov str., 175/1

111157@mail.ruНаучно-исследовательский институт терапии и профилактической медицины – филиал Федерального государственного бюджетного научного учреждения «Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук»Research Institutе of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences2021120120221742027Copyright © Евдокимова Н.Е., Стрюкова Е.В., Маслацов Н.А., Худякова А.Д., Волкова М.В., Логвиненко И.И., 20222022Евдокимова Н.Е., Стрюкова Е.В., Маслацов Н.А., Худякова А.Д., Волкова М.В., Логвиненко И.И.Evdokimova N.E., Striukova E.V., Maslatsov N.A., Khudyakova A.D., Volkova M.V., Logvinenko I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/540

Цель исследования было оценить связь параметров липидного профиля и индекса атерогенности плазмы, а также антропометрических параметров с тяжестью течения новой коронавирусной инфекции COVID-19 у женщин. Материал и методы. Выполнено одномоментное исследование, в которое включено 138 женщин в возрасте 29–82 лет, не менее двух месяцев назад перенесших новую коронавирусную инфекцию COVID-19 с легким (n = 61), среднетяжелым (n = 70) и тяжелым (n = 7) течением. У пациенток определяли индекс массы тела (ИМТ), окружность талии (ОТ) и бедер (ОБ), индекс ОТ/ОБ, содержание общего холестерина (ХС), триглицеридов, липопротеинов высокой (ЛПВП) и низкой (ЛПНП) плотности, рассчитывали индекс атерогенности плазмы (AIP). Результаты. Содержание ХС ЛПВП было достоверно меньше у женщин, перенесших COVID-19 в тяжелой форме, чем у пациенток со среднетяжелым течением инфекции (р = 0,046). ИМТ был больше в группе среднетяжелого течения по сравнению с легким (р = 0,026), ОБ – у пациенток с тяжелым течением по сравнению с больными с легким течением (р = 0,039), AIP – у женщин с тяжелым течением по сравнению с пациентками со среднетяжелым и легким течением (р = 0,043 и р = 0,04 соответственно). Логистический регрессионный анализ показал, что среднетяжелое течение COVID-19 связано с ИМТ (отношение шансов (OR) = 1,090, 95%-й доверительный интервал (95 % CI) 1,019–1,166, р = 0,012), а тяжелое течение – с ОТ (OR = 1,041, 95 % CI 1,001–1,084, р = 0,046), значением AIP ≥ 0,11 (по сравнению как с легким (OR = 13,824, 95 % CI 1,505– 126,964, р = 0,02), так и со среднетяжелым (OR = 11,579, 95 % CI 1,266–105,219, р = 0,03) течением) и уровнем ЛПВП < 40 мг/дл (соответственно OR = 14,750, 95 % CI 2,317–93,906, р = 0,004 и OR = 8,000, 95 % CI 1,313–48,538, р = 0,024). Заключение. Пациенты со среднетяжелым и тяжелым течением новой коронавирусной инфекции имеют более высокие величины ИМТ, ОБ, AIP, меньшее содержание ЛПВП. Вероятность среднетяжелого течения COVID-19 связана с увеличением ИМТ, а тяжелого – с более выраженным значением ОТ, AIP ≥ 0,11 и уровнем ЛПВП < 40 мг/дл.

Background: Our study aimed to assess the relationship between the parameters of the lipid profile, atherogenic index of plasma (AIP), anthropometry influence with the severity of the new coronavirus infection COVID-19 in women. Material and methods. The study design was a cross-sectional study. The research included 138 women aged 29–82 years who had undergone a new coronavirus infection COVID-19 at least two months ago. Participants were divided into three groups by severity of infection: mild (n = 61), moderate (n = 70) and severe (n = 7). Body mass index, waistline and hip circumference, waistline circumference to hip circumference index, total cholesterol, triglycerides, HDL, LDL, AIP were calculated. Statistical processing of the obtained results was carried out using the SPSS software package (version 20.0) using the Mann-Whitney test, univariate logistic regression analysis, Pearson chi-squared test. Results. The levels of HDL-cholesterol were significantly lower in group 3 compared with the level of HDL-cholesterol in women in group 2 (p2-3 = 0.046). BMI was higher in the moderately severe group compared to the mild one (26.32 [23.305; 30.4] versus 28.78 [24.72; 34.77], p1-2 = 0.026). Hip circumference was higher in patients with severe COVID-19 than in patients with mild course (104 [98; 112] versus 114 [109.5; 126], p1-3 = 0.039), AIP was higher in women with severe course compared to women with moderate and mild course (p1-3 = 0.043, p2-3 = 0.04). The results of the logistic regression analysis showed that the moderate course of COVID-19 is associated with BMI (OR = 1.09, 95 % CI 1.019–1.166, p1-2 = 0.012), and the severe course with WC (OR = 1.041, 95 % CI 1.001–1.084, p1-3 = 0.046), AIP value ≥ 0.11 (OR = 13.824, 95 % CI 1.505–126.964, p1-3 = 0.02; OR = 11,579, 95 % CI 1,266–105,219, p2-3 = 0.03) and HDL level < 40 mg/dl (OR = 14,750, 95 % CI 2,317–93,906, p1-3 = 0.004; OR = 8,000, 95 % CI 1,313– 48,538, p1-3 = 0.024). Conclusion. Patients from the group with moderate and severe course of the new coronavirus infection have higher body mass index, hip circumference, AIP, lower HDL values. The chance of a moderate course of COVID-19 is associated with an increased BMI value, and a severe course with WC, AIP ≥ 0.11 and HDL level < 40 mg/dl.

женщиныCOVID-19степень тяжестихолестерин липопротеидов высокой плотностидислипидемияиндекс атерогенности плазмыwomenCOVID-19severityhigh-density lipoprotein cholesteroldyslipidemiaatherogenic index of plasmaИсследование выполнено в рамках Бюджетной темы № АААА-А19-119101490005-5 «Формирование когорт детского, подросткового, молодого населения для изучения механизмов и особенностей жизненного цикла человека в российской популяции».The study was supported by State Budget theme no. AAAA19-119101490005-5 «Formation of cohorts of children, adolescents, young people to study the mechanisms and features of the human life cycle in the Russian population».ReferencesSituation Reports [Internet]. Situation Reports. 2021 [cited 2021July22]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---20-july-2021Situation Reports [Internet]. Situation Reports. 2021 [cited 2021July22]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---20-july-2021Sorokin A.V., Karathanasis S.K., Yang Z.H. et al. COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches. FASEB J., 2020; 34 (8): 9843– 9853. doi:10.1096/fj.202001451Sorokin A.V., Karathanasis S.K., Yang Z.H. et al. COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches. FASEB J., 2020; 34 (8): 9843– 9853. doi:10.1096/fj.202001451Choi G.J., Kim H.M., Kang H. The potential role of dyslipidemia in COVID-19 severity: an umbrella review of systematic reviews. J. Lipid Atheroscler., 2020; 9 (3): 435–448. doi:10.12997/jla.2020.9.3.435Choi G.J., Kim H.M., Kang H. The potential role of dyslipidemia in COVID-19 severity: an umbrella review of systematic reviews. J. Lipid Atheroscler., 2020; 9 (3): 435–448. doi:10.12997/jla.2020.9.3.435Gallo Marin B., Aghagoli G., Lavine K. et al. Predictors of COVID-19 severity: A literature review. Rev. Med. Virol., 2021; 31 (1): 1–10. doi:10.1002/rmv.2146Gallo Marin B., Aghagoli G., Lavine K. et al. Predictors of COVID-19 severity: A literature review. Rev. Med. Virol., 2021; 31 (1): 1–10. doi:10.1002/rmv.2146Wei X., Zeng W., Su J. et al. Hypolipidemia is associated with the severity of COVID-19. J. Clin. Lipidol., 2020; 14 (3): 297–304. doi:10.1016/j.jacl.2020.04.008Wei X., Zeng W., Su J. et al. Hypolipidemia is associated with the severity of COVID-19. J. Clin. Lipidol., 2020; 14 (3): 297–304. doi:10.1016/j.jacl.2020.04.008Turgay Yıldırım Ö., Kaya Ş. The atherogenic index of plasma as a predictor of mortality in patients with COVID-19. Heart Lung, 2021; 50 (2): 329–333. doi:10.1016/j.hrtlng.2021.01.016Turgay Yıldırım Ö., Kaya Ş. The atherogenic index of plasma as a predictor of mortality in patients with COVID-19. Heart Lung, 2021; 50 (2): 329–333. doi:10.1016/j.hrtlng.2021.01.016Nguemaïm N.F., Mbuagbaw J., Nkoa T. Serum lipid profile in highly active antiretroviral therapynaïve HIV-infected patients in Cameroon: a casecontrol study. HIV Med., 2010; 11 (6): 353–359. doi:10.1111/j.1468-1293.2009.00784.xNguemaïm N.F., Mbuagbaw J., Nkoa T. Serum lipid profile in highly active antiretroviral therapynaïve HIV-infected patients in Cameroon: a casecontrol study. HIV Med., 2010; 11 (6): 353–359. doi:10.1111/j.1468-1293.2009.00784.xDobiasova M., Frohlich J., Sedova M. et al. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J. Lipid Res., 2011; 52 (3): 566–571. doi:10.1194/jlr.P011668Dobiasova M., Frohlich J., Sedova M. et al. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J. Lipid Res., 2011; 52 (3): 566–571. doi:10.1194/jlr.P011668Abu-Farha M., Thanaraj T.A., Qaddoumi M.G. et al. The role of lipid metabolism in COVID-19 virus infection and as a drug target. Int. J. Mol. Sci., 2020; 21 (10): 3544. doi:10.3390/ijms21103544Abu-Farha M., Thanaraj T.A., Qaddoumi M.G. et al. The role of lipid metabolism in COVID-19 virus infection and as a drug target. Int. J. Mol. Sci., 2020; 21 (10): 3544. doi:10.3390/ijms21103544Lorizate M., Kräusslich H.G. Role of lipids in virus replication. Cold Spring Harb. Perspect Biol., 2011; 3 (10): a004820. doi:10.1101/cshperspect.a004820Lorizate M., Kräusslich H.G. Role of lipids in virus replication. Cold Spring Harb. Perspect Biol., 2011; 3 (10): a004820. doi:10.1101/cshperspect.a004820Kim J.A., Montagnani M., Chandrasekran S., Quon M.J. Role of lipotoxicity in endothelial dysfunction. Heart Fail. Clin., 2012; 8 (4): 589–607. doi:10.1016/j.hfc.2012.06.012Kim J.A., Montagnani M., Chandrasekran S., Quon M.J. Role of lipotoxicity in endothelial dysfunction. Heart Fail. Clin., 2012; 8 (4): 589–607. doi:10.1016/j.hfc.2012.06.012Froldi G., Dorigo P. Endothelial dysfunction in coronavirus disease 2019 (COVID-19): Gender and age influences. Med. Hypotheses, 2020; 144: 110015. doi:10.1016/j.mehy.2020.110015Froldi G., Dorigo P. Endothelial dysfunction in coronavirus disease 2019 (COVID-19): Gender and age influences. Med. Hypotheses, 2020; 144: 110015. doi:10.1016/j.mehy.2020.110015Kaji H. High-density lipoproteins and the immune system. J. Lipids, 2013; 2013: 684903. doi:10.1155/2013/684903Kaji H. High-density lipoproteins and the immune system. J. Lipids, 2013; 2013: 684903. doi:10.1155/2013/684903McKechnie J.L., Blish C.A. The innate immune system: fighting on the front lines or fanning the flames of COVID-19? Cell Host Microbe, 2020; 27 (6): 863– 869. doi:10.1016/j.chom.2020.05.009McKechnie J.L., Blish C.A. The innate immune system: fighting on the front lines or fanning the flames of COVID-19? Cell Host Microbe, 2020; 27 (6): 863– 869. doi:10.1016/j.chom.2020.05.009Wang G., Zhang Q., Zhao X. et al. Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study. Lipids Health Dis., 2020; 19 (1): 204. doi:10.1186/s12944-020-01382-9Wang G., Zhang Q., Zhao X. et al. Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study. Lipids Health Dis., 2020; 19 (1): 204. doi:10.1186/s12944-020-01382-9Fan J., Wang H., Ye G. et al. Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism, 2020; 107: 154243. doi:10.1016/j.metabol.2020.154243Fan J., Wang H., Ye G. et al. Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism, 2020; 107: 154243. doi:10.1016/j.metabol.2020.154243Aparisi Á., Iglesias-Echeverría C., Ybarra-Falcón C. et al. Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19. Nutr. Metab. Cardiovasc. Dis., 2021; 31 (9): 2619– 2627. doi:10.1016/j.numecd.2021.06.016Aparisi Á., Iglesias-Echeverría C., Ybarra-Falcón C. et al. Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19. Nutr. Metab. Cardiovasc. Dis., 2021; 31 (9): 2619– 2627. doi:10.1016/j.numecd.2021.06.016Peters S.A.E., MacMahon S., Woodward M. Obesity as a risk factor for COVID-19 mortality in women and men in the UK biobank: Comparisons with influenza/ pneumonia and coronary heart disease. Diabetes Obes. Metab., 2021; 23 (1): 258–262. doi:10.1111/dom.14199Peters S.A.E., MacMahon S., Woodward M. Obesity as a risk factor for COVID-19 mortality in women and men in the UK biobank: Comparisons with influenza/ pneumonia and coronary heart disease. Diabetes Obes. Metab., 2021; 23 (1): 258–262. doi:10.1111/dom.14199Alamdari N.M., Rahimi F.S., Afaghi S. et al. The impact of metabolic syndrome on morbidity and mortality among intensive care unit admitted COVID-19 patients. Diabetes Metab. Syndr., 2020; 14 (6): 1979– 1986. doi:10.1016/j.dsx.2020.10.012Alamdari N.M., Rahimi F.S., Afaghi S. et al. The impact of metabolic syndrome on morbidity and mortality among intensive care unit admitted COVID-19 patients. Diabetes Metab. Syndr., 2020; 14 (6): 1979– 1986. doi:10.1016/j.dsx.2020.10.012Freuer D., Linseisen J., Meisinger C. Impact of body composition on COVID-19 susceptibility and severity: A two-sample multivariable Mendelian randomization study. Metabolism, 2021; 118: 154732. doi:10.1016/j.metabol.2021.154732Freuer D., Linseisen J., Meisinger C. Impact of body composition on COVID-19 susceptibility and severity: A two-sample multivariable Mendelian randomization study. Metabolism, 2021; 118: 154732. doi:10.1016/j.metabol.2021.154732Onat A., Can G., Kaya H., Hergenç G. «Atherogenic index of plasma» (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J. Clin. Lipidol., 2010; 4 (2): 89–98. doi:10.1016/j.jacl.2010.02.005Onat A., Can G., Kaya H., Hergenç G. «Atherogenic index of plasma» (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J. Clin. Lipidol., 2010; 4 (2): 89–98. doi:10.1016/j.jacl.2010.02.005Yildiz G., Duman A., Aydin H. et al. Evaluation of association between atherogenic index of plasma and intima-media thickness of the carotid artery for subclinic atherosclerosis in patients on maintenance hemodialysis. Hemodial. Int., 2013; 17 (3): 397–405. doi:10.1111/hdi.12041Yildiz G., Duman A., Aydin H. et al. Evaluation of association between atherogenic index of plasma and intima-media thickness of the carotid artery for subclinic atherosclerosis in patients on maintenance hemodialysis. Hemodial. Int., 2013; 17 (3): 397–405. doi:10.1111/hdi.12041Niroumand S., Khajedaluee M., Khadem-Rezaiyan M. et al. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Med. J. Islam Repub. Iran, 2015; 29: 240.Niroumand S., Khajedaluee M., Khadem-Rezaiyan M. et al. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Med. J. Islam Repub. Iran, 2015; 29: 240.Turgay Yıldırım Ö., Akşit E., Aydın F. et al. Evaluation of atherogenic index of plasma levels at hypertensive patients. ACEM, 2019; 4 (2): 72–75. doi:10.25000/acem.563986Turgay Yıldırım Ö., Akşit E., Aydın F. et al. Evaluation of atherogenic index of plasma levels at hypertensive patients. ACEM, 2019; 4 (2): 72–75. doi:10.25000/acem.563986

The authors declare that there are no conflicts of interest present.